All In Biotech

Drug Trial Radar · NCT02160782

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

Long-Term, Open-Label Study With a Double-Blind, Placebo-Controlled, Randomized Drug Withdrawal Period of LUM001 (Maralixibat), an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Alagille Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Oct 28, 2014

Primary completion

May 28, 2020

Study completion May 28, 2020

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as maralixibat or MRX).

Conditions

  • Alagille Syndrome

Interventions

  • LUM001 (Maralixibat)Drug

    LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.

  • PlaceboDrug

    Placebo will be administered orally once daily during randomized withdrawal period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18Time frame: Week 18 to Week 22

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Hospital Westmead

    Westmead, New South Wales, Australia

  • The Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hopital Femme Mere Enfant De Lyon

    Bron, France

  • Hopital Necker-Enfants Malades

    Paris, France

  • Hopital Kremlin Bicetre

    Paris, France

  • The Children's Memorial Health Institute

    Warsaw, Poland

  • Hospital Universitario La Paz- Hospital Materno Infantil

    Madrid, Spain

  • Paediatric Liver Center, Kings College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.